Osteoarthritis - Pipeline Insight, 2025
Description
DelveInsight’s, “Osteoarthritis - Pipeline Insight, 2025” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Osteoarthritis: Overview
Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work. Osteoarthritis is the most common type of arthritis, characterized by the gradual breakdown of cartilage in joints, leading to pain, stiffness, and swelling. Symptoms often include joint pain that worsens with activity and improves with rest, stiffness lasting less than 30 minutes after inactivity, and a sensation of joint instability or looseness. Affected joints may also produce a grinding or creaking sound during movement, and swelling can occur, particularly after prolonged use.
Osteoarthritis (OA) pathogenesis is a multifaceted process involving the entire joint, characterized by the interplay of various tissues such as articular cartilage, subchondral bone, synovium, and ligaments. Initially thought to be primarily a disease of cartilage, recent research reveals that OA is driven by complex mechanisms including mechanical stress, inflammation, and biochemical changes. Key factors in OA development include the activation of pro-inflammatory cytokines like interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), which contribute to cartilage degradation and synovial inflammation. Additionally, alterations in the extracellular matrix, increased production of matrix metalloproteinase (MMPs), and changes in subchondral bone remodeling play critical roles in the disease's progression. This holistic view underscores the need for targeted therapeutic strategies that address the multifactorial nature of OA, moving beyond traditional approaches focused solely on cartilage damage.
The diagnosis of osteoarthritis involves a comprehensive evaluation that includes a detailed medical history, physical examination, and imaging tests. Healthcare providers assess the patient's symptoms, such as joint pain, stiffness, and any mechanical issues like grinding sounds during movement. During the physical exam, the doctor examines the affected joints for swelling, tenderness, and range of motion. Imaging techniques, primarily X-rays, are utilized to identify characteristic changes such as joint space narrowing and the presence of osteophytes (bone spurs). In some cases, MRI or CT scans may be employed for a more detailed view of the joint structures. Treatment for osteoarthritis (OA) focuses on alleviating symptoms, improving joint function, and enhancing the quality of life. A comprehensive approach typically includes non-pharmacologic strategies such as physical therapy, which helps strengthen muscles around the joints and improve flexibility, and weight management to reduce stress on affected joints. Pharmacologic options include nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief and inflammation, as well as acetaminophen for mild pain.
""Osteoarthritis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoarthritis pipeline landscape is provided which includes the disease overview and Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Osteoarthritis Emerging Drugs
Further product details are provided in the report……..
Osteoarthritis: Therapeutic Assessment
This segment of the report provides insights about the different Osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:
Osteoarthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Osteoarthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteoarthritis drugs.
Osteoarthritis Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Osteoarthritis: Overview
Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work. Osteoarthritis is the most common type of arthritis, characterized by the gradual breakdown of cartilage in joints, leading to pain, stiffness, and swelling. Symptoms often include joint pain that worsens with activity and improves with rest, stiffness lasting less than 30 minutes after inactivity, and a sensation of joint instability or looseness. Affected joints may also produce a grinding or creaking sound during movement, and swelling can occur, particularly after prolonged use.
Osteoarthritis (OA) pathogenesis is a multifaceted process involving the entire joint, characterized by the interplay of various tissues such as articular cartilage, subchondral bone, synovium, and ligaments. Initially thought to be primarily a disease of cartilage, recent research reveals that OA is driven by complex mechanisms including mechanical stress, inflammation, and biochemical changes. Key factors in OA development include the activation of pro-inflammatory cytokines like interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), which contribute to cartilage degradation and synovial inflammation. Additionally, alterations in the extracellular matrix, increased production of matrix metalloproteinase (MMPs), and changes in subchondral bone remodeling play critical roles in the disease's progression. This holistic view underscores the need for targeted therapeutic strategies that address the multifactorial nature of OA, moving beyond traditional approaches focused solely on cartilage damage.
The diagnosis of osteoarthritis involves a comprehensive evaluation that includes a detailed medical history, physical examination, and imaging tests. Healthcare providers assess the patient's symptoms, such as joint pain, stiffness, and any mechanical issues like grinding sounds during movement. During the physical exam, the doctor examines the affected joints for swelling, tenderness, and range of motion. Imaging techniques, primarily X-rays, are utilized to identify characteristic changes such as joint space narrowing and the presence of osteophytes (bone spurs). In some cases, MRI or CT scans may be employed for a more detailed view of the joint structures. Treatment for osteoarthritis (OA) focuses on alleviating symptoms, improving joint function, and enhancing the quality of life. A comprehensive approach typically includes non-pharmacologic strategies such as physical therapy, which helps strengthen muscles around the joints and improve flexibility, and weight management to reduce stress on affected joints. Pharmacologic options include nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief and inflammation, as well as acetaminophen for mild pain.
""Osteoarthritis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoarthritis pipeline landscape is provided which includes the disease overview and Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Osteoarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Osteoarthritis.
This segment of the Osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Osteoarthritis Emerging Drugs
- Lorecivivint: Biosplice Therapeutics
- EP-104IAR: Eupraxia Pharmaceuticals
- DFV890: Novartis
- 4P004: 4P-Pharma
- GNSC 001: Genascence
Further product details are provided in the report……..
Osteoarthritis: Therapeutic Assessment
This segment of the report provides insights about the different Osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Osteoarthritis
- There are approx. 100+ key companies which are developing the therapies for Osteoarthritis. The companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e. Phase III include, Biosplice Therapeutics.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Osteoarthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Osteoarthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteoarthritis drugs.
Osteoarthritis Report Insights
- Osteoarthritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Osteoarthritis drugs?
- How many Osteoarthritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteoarthritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Osteoarthritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Osteoarthritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Biosplice Therapeutics
- Cynata Therapeutics
- Bone Therapeutics S.A
- Regeneron Pharmaceuticals
- Techfields Pharma
- Ampio Pharmaceuticals
- Asahi Kasei Pharma
- Taiwan Bio Therapeutics
- OliPass Corporation
- Bioventus
- Medipost
- LG Chem
- ICM Biotech
- Cells for Cells SA
- GWOXI Stem Cell Applied Technology
- UnicoCell Biomed
- Magellan Biologicals
- Levicept
- Arthrogen
- Personalized Stem Cells
- Peptinov
- Orient Europharma
- ZYUS Life Sciences
- Lubris Biopharma
- Saol Therapeutics
- Ageless Biotech
- Synartro AB
- Plakous Therapeutics
- Ribomic
- Meluha Therapeutics
- Lorecivivint
- CYP 004
- JTA-004
- Fasinumab
- X0002
- Ampion
- AK1830
- Chondrochymal
- OLP-1002
- PTP-001
- SMUP-IA-01
- LG00034053
- ICM-203
- Cellistem
- GXCPC1
- Elixcyte
- Magellan Stem Cells
- LEVI 04
- ART-I02
- PSC-01
- PPV 06
- 2ccPA
- Trichomylin
- Human Lubricin
- SIL 1002
- Adipose dervied stem cells
- SYN321
- Protego-PD
- RBM-010
- Chondrogen
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Table of Contents
280 Pages
- Introduction
- Executive Summary
- Osteoarthritis: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Osteoarthritis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Lorecivivint: Biosplice Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- EP-104IAR: Eupraxia Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- GNSC 001: Genascence
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Osteoarthritis Key Companies
- Osteoarthritis Key Products
- Osteoarthritis- Unmet Needs
- Osteoarthritis- Market Drivers and Barriers
- Osteoarthritis- Future Perspectives and Conclusion
- Osteoarthritis Analyst Views
- Osteoarthritis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
